32 results about "Left ventricular ejection" patented technology

The invention provides a left heart data analysis method and system based on image segmentation, and relates to the technical field of medical image processing. Comprising the following steps: acquiring cardiac ultrasound image data and preprocessing; performing image segmentation on the preprocessed image data to obtain a segmentation result including a left ventricle, a left ventricular wall and a left atrium; searching a boundary line of the left ventricle and the left atrium, selecting two boundary points corresponding to the minimum and maximum abscissas in the boundary line as left and right mitral valve ring points respectively, and establishing a long axis based on the mitral valve ring midpoint and the cardiac apex point; modeling the ventricle into a structure formed by superposing a plurality of discs along the long axis direction, and obtaining the diameter of the corresponding disc; based on the obtained diameters of the corresponding discs, the left ventricular volumes in the diastolic period and the systolic period are calculated respectively, and the left ventricular ejection fraction is calculated. According to the method, image segmentation and geometric modeling are fused to achieve accurate calculation of the cardiac ejection fraction, meanwhile, the accuracy of cardiac structure image segmentation is improved, and an interpretable ejection fraction estimation process is achieved.

The invention belongs to the technical field of new application of medicines, and provides application of Zhongwinning in preparation of a medicine for treating ischemic heart disease. In a myocardial ischemia rat model test, Zhongwinning shows that the Zhongwinning can obviously improve the left ventricular ejection fraction and the left ventricular short-axis shortening rate of a myocardial ischemia rat; in addition, the rising and falling rates of the ventricular pressure of the myocardial ischemia rats can be remarkably improved, and it is indicated that Zhongutanin can effectively recover the left ventricular systolic function and can effectively repair myocardial injury caused by myocardial ischemia reperfusion. Therefore, according to the experimental research result of the application, the Zhongwinning has a certain application prospect in treating the ischemic heart disease.

This invention belongs to the field of novel pharmaceutical applications, providing the application of Zhongwu Ning in the preparation of drugs for treating ischemic heart disease. In rat models of myocardial ischemia, Zhongwu Ning significantly increased the left ventricular ejection fraction and left ventricular fractional shortening rate; it also significantly improved the rate of increase and decrease of intracardiac pressure in rats with myocardial ischemia, indicating that Zhongwu Ning can effectively restore left ventricular systolic function and effectively repair myocardial damage caused by myocardial ischemia-reperfusion. Therefore, based on the experimental research results of this application, Zhongwu Ning has certain application prospects in the treatment of ischemic heart disease.

The invention discloses a motion intervention heart failure repair method based on Lgmn signal regulation and control, and relates to the technical field of heart failure treatment. According to the method, through aerobic exercise training (AET) with specific parameters, expression of Legumain (Lgmn) genes in macrophages is regulated in a targeted mode, the interburial effect of the macrophages is enhanced, then cell communication between the macrophages and cardiac muscle cells is enhanced, removal of the vertical death cardiac muscle cells is promoted, myocardial fibrosis and inflammatory response are relieved, and the effect of treating myocardial fibrosis is achieved. Finally, ventricular remodeling and heart functions of chronic heart failure (CHF) mice are improved. Experimental verification shows that the exercise intervention method can significantly improve the left ventricular ejection fraction (LVEF) and shortening fraction (FS) of CHF model animals, reduce the left ventricular end-of-systole inner diameter (LVESD), reduce myocardial cell apoptosis and necrosis, and promote inflammation regression. Drug intervention is not needed, safety is high, operation is easy and convenient, and a new effective way is provided for clinical rehabilitation treatment of heart failure.

The traditional Chinese medicine composition is characterized by being prepared from the following traditional Chinese medicinal materials in parts by weight: 3 to 9 parts of rhizoma chuanxiong, 3 to 7 parts of rhizoma atractylodis, 6 to 14 parts of rhizoma cyperi, 6 to 14 parts of medicated leaven, 3 to 7 parts of euphorbia helioscopia, 10 to 20 parts of poria cocos, 8 to 12 parts of fructus trichosanthis, 8 to 12 parts of radix salviae miltiorrhizae, 8 to 12 parts of herba epimedii, 3 to 9 parts of pepper, 8 to 12 parts of herba patriniae and 8 to 12 parts of caulis spatholobi. After the traditional Chinese medicine composition is used for treating acute myocardial infarction, a remarkable effect is achieved on PCI postoperative improvement of acute myocardial infarction, troponin and creatine kinase isoenzyme indexes are reduced, and the left ventricular ejection fraction is in a normal range after cardiac color ultrasound display treatment. Through comprehensive conditioning, symptoms such as chest distress, chest pain, shortness of breath and hypodynamia of patients are improved, cardiac function recovery is promoted, complications such as restenosis and heart failure are prevented, and life quality is improved.

The invention provides a method for measuring the left ventricular ejection fraction of a dynamic echocardiography. The method comprises the following steps: inputting a to-be-identified echocardiogram sequence into a neural network segmentation model based on multi-frame feature aggregation, then performing spatial feature coding on each frame of image of the to-be-identified echocardiogram sequence through a spatial feature encoder structure to obtain a spatial feature map corresponding to each frame of image, and finally, identifying the to-be-identified echocardiogram sequence according to the spatial feature map. Performing cross-frame and cross-section spatio-temporal feature aggregation on the spatial feature pattern through a spatio-temporal feature aggregation structure to obtain global spatio-temporal features including time sequence information of a heart apex two-cavity section and a heart apex four-cavity section; the left ventricular ejection fraction determining method comprises the steps of generating a left ventricular membrane segmentation mask of a terminal diastole frame and a terminal systole frame on the basis of global spatial-temporal characteristics and spatial shallow layer characteristics corresponding to the terminal diastole frame and the terminal systole frame, and finally determining the left ventricular ejection fraction on the basis of the left ventricular membrane segmentation mask of the terminal diastole frame and the terminal systole frame.

The invention discloses a left ventricular ejection fraction regression prediction system based on transfer learning and multi-view fusion, and belongs to the field of medical image analysis. The problem that an existing deep learning method is poor in left ventricular ejection fraction prediction accuracy is solved. According to the method, the A4C view angle echocardiogram data and the PSAX view angle echocardiogram data are subjected to independent model pre-training, and then the pre-trained model parameters are subjected to transfer learning, so that a better initialization effect can be obtained, and model convergence and performance optimization are accelerated. The double-view-angle fusion regression module can well combine spatial and temporal features output by the two single-view-angle models, feature relevance of echocardiogram data of the two view angles is greatly utilized, and the accuracy of final model prediction can be improved. In addition, through fusion of the multi-view echocardiogram data features, the influence of anatomical structure differences on the detection result is effectively reduced. The method can be applied to left ventricular ejection fraction regression prediction.

The invention discloses a method for predicting heart failure based on left ventricular ejection fraction, which develops and trains a primitive model to automatically provide help and evaluate the level of clinical decision based on LVEF heart failure. The training model is prevented from using any or biased clinical variables, and the following two steps are ensured: investigating the statistical significance of each variable to distinguish the three categories; secondly, a novel dimension reduction technology is adopted to visually observe the characterization of the optimal variable in the radial direction, and each LVEF-based HF category is separated; and on the basis, the performance of the developed model is trained, the importance of the most important clinical variables is discussed, and the significance of the clinical variables is explained in detail based on the application of LVEF-based deep learning in HF analysis, so that patient data of three heart failure types are distinguished.

The invention belongs to the field of new application of medicines, and particularly relates to application of Oloinab in preparation of medicines for treating and / or preventing ischemic cardiomyopathy. Animal experiments prove that Oloinab can remarkably improve the left ventricular ejection fraction and the left ventricular short axis shortening rate of myocardial infarction model mice, improve the heart function and reduce the cardiac fibrosis area, and it is indicated that Oloinab has the effect of improving myocardial remodeling and systolic dysfunction. The discovery provides a new treatment strategy for ischemic cardiomyopathy, and has an important clinical application prospect.

This application provides an ultrasound cardiac dynamic monitoring system and method, relating to the field of ultrasound cardiac function dynamic monitoring technology. The system includes: a patch-type ultrasound probe, a hydrogel patch, a wearable hardware module, and a cardiac function analysis module. The cardiac function analysis module is configured to: receive the ultrasound image; determine a target sampling line in the ultrasound image based on a reinforcement learning model; control the wearable hardware module to acquire M-mode images along the target sampling line; input the M-mode images into a deep learning model to output the key point positions of the left ventricular septum and the left ventricular posterior wall at end-diastole and end-systole based on the deep learning model; calculate the left ventricular ejection fraction (LVEF) based on the LVEF and the key point positions; the LVEF represents the dynamic monitoring and detection results of cardiac function. This system can improve the effectiveness and accuracy of dynamic cardiac monitoring.

The present invention discloses a traditional Chinese medicine preparation for preventing and / or treating myocardial infarction, its preparation method and application, belonging to the technical field of pharmaceuticals. The traditional Chinese medicine is obtained by extracting Areca catechu with 20% - 95% ethanol. The present invention first reveals that the Areca catechu extract has an anti-myocardial infarction effect. The experimental results show that the crude extract of Areca catechu can significantly inhibit H2O2-induced cardiomyocyte death, improve the left ventricular ejection fraction of myocardial infarction mice, and reduce the myocardial infarction area, and the effect is equivalent to that of the positive drug Suxiao Jiuxin Pills, while arecoline has no cardiomyocyte protection effect. The present invention is of natural origin, simple to prepare, and low in cost, and can be used as a new supplement or alternative for clinical prevention and treatment of myocardial infarction, and has important clinical value and application prospects.

Embodiments of the present disclosure provide a left ventricular ejection fraction prediction method, device, equipment, medium and product. The method comprises: acquiring a heart ultrasound sequence of a heart part; inputting the heart ultrasound sequence into a target processing model trained in advance to output a left ventricular graph sequence which has been marked with a left ventricle; determining a plurality of effective image pairs according to area change rates of a plurality of left ventricular segmentation images in the left ventricular graph sequence, and determining left ventricular end-diastolic volumes and left ventricular end-systolic volumes corresponding to each effective image pair; and determining a left ventricular ejection fraction according to the left ventricular end-diastolic volumes and the left ventricular end-systolic volumes associated with the plurality of effective image pairs. The technical solution of the embodiments of the present disclosure processes the heart ultrasound sequence based on the target processing model to determine the left ventricular ejection fraction, which can weaken the influence of factors such as poor single-frame quality, respiratory jitter and arrhythmia, thereby achieving the effect of improving the accuracy of the left ventricular ejection fraction.

The invention belongs to the field of biological materials and cardiovascular repair, and relates to hydrogel for repairing after myocardial infarction as well as a preparation method and application of the hydrogel. The hydrogel consists of chitosan or a derivative thereof, silk fibroin, tannic acid and a biological cross-linking agent in a weight ratio of 3: (0.8-1.2): (0.1-3.0): (0.1-0.2). According to the invention, tannic acid is introduced into the chitosan-silk fibroin composite hydrogel as a cross-linking agent and a rigidity reinforcing agent, so that the compressive strength of the hydrogel is increased from 34.4 kPa to 84.45 kPa, and the elastic modulus is increased to gt; and the mechanical property of the material is matched with that of the myocardial tissue. Meanwhile, the hydrogel can realize multi-dimensional coordinated regulation and control on oxidative stress, inflammatory response and myocardial fibrosis: in a myocardial infarction model, the hydrogel enables the left ventricular ejection fraction (LVEF) to be increased by 25%, the active oxygen clearance rate to be increased by 45%, the inflammatory cell infiltration to be reduced by 45%, the proinflammatory cytokine (IL-6 / TNF-alpha) level to be reduced by 30%, and the fibrosis area to be reduced by 40%; therefore, the heart failure process after myocardial infarction is effectively delayed.

The invention relates to a left ventricular mass correction ejection fraction prediction risk system, which comprises a data acquisition module used for acquiring the measurement data of the left ventricular ejection fraction and the left ventricular mass of a patient; the correction calculation module is in communication connection with the data acquisition module and is used for calculating a correction parameter based on the left ventricle quality according to the measurement data; the risk assessment module is connected with the correction calculation module and used for constructing a risk assessment model based on the correction parameters and the clinical covariables and outputting an individualized risk layering result, and the correction calculation module can analyze and establish a relation model of the correction parameters and the cardiac event risks through a restrictive cubic spline and output the individualized risk layering result. Comprising the steps that data standardization processing is carried out on correction parameters, segmentation fitting is carried out based on preset spline nodes, fitting curve coefficients are solved through a least square method to form a nonlinear relation curve, the model goodness of fit is evaluated through statistical test, and the correction parameters comprise one or more of LVEF / LVM, LVEF / LVM / BSA and LVEF / LVM / BMI.

The invention discloses application of Eraffibulaol in preparation of a medicine for treating myocardial remodeling of diabetic cardiomyopathy, and belongs to the technical field of medicines. By researching the influence of the Eraffibularox on diabetic cardiomyopathy-induced myocardial remodeling model mice, it is confirmed that the Eraffibularox can relieve myocardial remodeling, and heart functions such as left ventricular ejection fraction and the like are reversed and improved at first; secondly, the pathological staining cardiac hypertrophy and fibrosis level is reduced, and the marker level is reduced; finally, it is found that the traditional Chinese medicine composition has an obvious improvement effect on glucose and lipid metabolism disorder in reconstructed heart tissue. The invention provides a novel application of Eraffibulanol in preparation of a medicine for treating myocardial remodeling of diabetic cardiomyopathy, and provides more treatment strategies for clinical treatment of diabetic cardiomyopathy.

The invention provides a construction method of a mouse heart failure model based on NCL gene myocardial specific knockout induction and application of NCL gene myocardial knockout. According to the method, Nclflox / flox and Myh6-Cre mice of 5-6 weeks old are used, NCL genes in cardiac muscle cells of the mice are specifically knocked out, the mice are continuously fed until the ejection fraction of a left ventricle is smaller than 50%, and the adult mouse heart failure model based on cardiac muscle cell nucleolin specific knockout is obtained. The successful construction of the model provides a key technical support for exploring heart diseases mediated by nucleolin-related pathways in myocardial cells, effectively fills the blank of demands of the research field in the aspect of experimental vectors, and has indispensable important significance for promoting heart disease mechanism research and transforming medical development.

Introduced here approaches to developing, training, and implementing algorithms to cardiac dysfunction through automated analysis of physiological data. As an example, a model may be developed and then trained to quantify left and right ventricular dysfunction using electrocardiogram waveform data that is associated with a population of individuals who are diverse in terms of age, gender, ethnicity, socioeconomic status, and the like. This approach to training allows the model to predict the presence of left and right ventricular dysfunction in a diverse population. Also introduced here is a regression framework for predicting numeric values of left ventricular ejection fraction.

The invention provides a deep learning-based method for automatically quantifying a left ventricular ejection fraction of an echocardiogram. Comprising the steps that an echocardiogram is obtained, and the echocardiogram comprises a cardiac apex four-cavity cardiac tangent plane A4C, a cardiac apex two-cavity cardiac tangent plane A2C and a cardiac apex three-cavity cardiac tangent plane A3C; determining a left ventricular region image of the echocardiogram; based on a left ventricle segmentation and key point detection method, determining a target image corresponding to the left ventricle region image; performing segmentation operation on the target image to obtain a left ventricle segmentation mask; performing key positioning operation on the target image to obtain key point position information of a left target image; the ejection fraction is determined based on the left ventricular segmentation mask and the keypoint location information. According to the method, a single neural network architecture is adopted to output the left ventricle segmentation mask and the key point position information at the same time, the error propagation problem caused by series connection of multiple models is avoided, and the accuracy and efficiency of obtaining the ejection fraction corresponding to the echocardiogram are improved.

A wearable, non-invasive, and non-intrusive hemodynamic monitoring device is disclosed for continuous monitoring of left ventricular (LV) hemodynamic waveforms and associated cardiovascular parameters. The device includes a flexible body with laterally extending electrode wings and a central rigid housing containing signal acquisition and transmission electronics. In various embodiments, the device includes either two or three wings configured for placement along the midsternal region and over the carotid arteries to enable simultaneous acquisition of electrical and mechanical signals via bioimpedance, ECG / EKG, and accelerometer sensors. Each wing incorporates tetrapolar bioimpedance electrode arrays, current injection electrodes, voltage sensing electrodes, and accelerometers to capture thoracic and cervical physiological signals necessary for estimating parameters such as left ventricular end diastolic pressure, extracellular fluid, left ventricular ejection fraction, cardiac out, stroke volume and QRS measures. The sensor signals are routed through flexible interconnects or magnetic mating connectors to the central housing. The system includes a wireless transmitter module supporting Bluetooth, Wi-Fi, or other wireless standards, a power supply and power management circuitry, and is constructed on ultra-thin, stretchable substrates composed of biocompatible flexible polymers. The modular design also includes user-serviceable magnetic connectors and optional adhesive layers for improved skin contact, thereby enabling continuous, real-time cardiovascular monitoring suitable for ambulatory and remote healthcare environments.

A wearable, non-invasive, and non-intrusive hemodynamic monitoring device is disclosed for continuous monitoring of left ventricular (LV) hemodynamic waveforms and associated cardiovascular parameters. The device includes a flexible body with laterally extending electrode wings and a central rigid housing containing signal acquisition and transmission electronics. In various embodiments, the device includes either two or three wings configured for placement along the midsternal region and over the carotid arteries to enable simultaneous acquisition of electrical and mechanical signals via bioimpedance, ECG / EKG, and accelerometer sensors. Each wing incorporates tetrapolar bioimpedance electrode arrays, current injection electrodes, voltage sensing electrodes, and accelerometers to capture thoracic and cervical physiological signals necessary for estimating parameters such as left ventricular end diastolic pressure, extracellular fluid, left ventricular ejection fraction, cardiac out, stroke volume and QRS measures. The sensor signals are routed through flexible interconnects or magnetic mating connectors to the central housing. The system includes a wireless transmitter module supporting Bluetooth, Wi-Fi, or other wireless standards, a power supply and power management circuitry, and is constructed on ultra-thin, stretchable substrates composed of biocompatible flexible polymers. The modular design also includes user-serviceable magnetic connectors and optional adhesive layers for improved skin contact, thereby enabling continuous, real-time cardiovascular monitoring suitable for ambulatory and remote healthcare environments.

The invention belongs to the technical field of biological medicines, and particularly discloses application of parabacteroides koreanum in preparation of a medicine for relieving myocardial ischemia-reperfusion injury. DNA sequencing and PCR are performed on excrement of MI / RI (myocardial ischemia reperfusion injury) model group mice, it is clear that P.goldsteinii is remarkably reduced in myocardial ischemia reperfusion injury, further research reveals that expression of myocardial necrosis factors CK-MB, LDH and cTnI of the MI / RI model mice is reduced under the action of P.goldsteinii, and expression of myocardial necrosis factors CK-MB, LDH and cTnI in myocardial necrosis factors CK-MB, LDH and cTnI in myocardial necrosis factors CK-MB, LDH and cTnI is reduced under the action of P.goldsteinii. After the P.Goldsteinii is subjected to intragastric administration, the left ventricular ejection fraction, the short-axis shortening fraction, the left ventricular end-systolic anterior wall thickness and the left ventricular end-systolic inner diameter of the heart are obviously increased, heart function decline caused by an MI / RI model is obviously relieved after the P.Goldsteinii is subjected to intragastric administration, and the P.Goldsteinii has a very good protection effect on myocardial ischemia reperfusion injury.

The application discloses a kind of left ventricular ejection fraction calculation method during cardiopulmonary resuscitation based on transesophageal echocardiogram, comprising the following steps: S1, obtain TEE image data and its corresponding segmentation mask, the segmentation mask is at least used to annotate the anatomical structure area of left ventricle;The image and mask data are preprocessed, and shape prior knowledge distillation subspace is constructed based on the mask data processed;S2, the preprocessed TEE data and segmentation mask are input into left ventricular ejection fraction calculation model, and the model is trained under the shape prior knowledge distillation subspace and loss function constraint;S3, the TEE data collected are input into left ventricular ejection fraction calculation model, realize the automatic segmentation of left ventricular region, and output the calculation result of ejection fraction.

The invention belongs to the field of biological medicines, and particularly relates to application of astragaloside in preparation of a medicine for treating myocardial remodeling after myocardial infarction. In-vivo and in-vitro experiments prove that the astragaloside can up-regulate the expression of Acox1, Cd36, Pgc1a and Cpt1a lipid metabolism related factors and improve lipid metabolism disorder after myocardial infarction; meanwhile, Acta2, Col1a1, Col3a1, Postn fibrosis factors and alpha-SMA expression are inhibited, and myocardial fibrosis after myocardial infarction is relieved; the left ventricular ejection fraction and the left ventricular short axis shortening rate can be remarkably increased, the left ventricular end diastolic inner diameter and the left ventricular end systolic inner diameter are reduced, and cardiac dysfunction caused by myocardial infarction is improved. The composition can block pathological circulation of lipid metabolism disorder, myocardial fibrosis and cardiac function decline in a targeted manner, the curative effect is dose-dependent, the safety is good, and a brand new effective drug choice is provided for clinical treatment of myocardial remodeling after myocardial infarction.

An in vitro method for detecting or diagnosing a Heart Failure subtype defined by left ventricular ejection fraction (EF) in a subject, comprises: (a) detecting or measuring at least one extracellular

The application discloses a left ventricular ejection fraction prediction device, comprising: a data input unit, an ultrasound image feature representation unit, a contrast learning unit based on multi-section two-dimensional echocardiogram and a left ventricular ejection fraction result prediction unit; the contrast learning unit comprises: an image representation module, a contrast image representation module, a negative sample queue storage module and a feature contrast module; the left ventricular ejection fraction result prediction unit is used for predicting the patient representation h k The combination is carried out and regression fitting is carried out to obtain a prediction result. The left ventricular ejection fraction prediction device can extract left ventricular related features from multiple different sections of two-dimensional echocardiograms of patients, improve ejection fraction prediction and application performance in a clinical environment, reduce the workload of professional data labeling, help better carry out corresponding clinical research, and help patients obtain better diagnosis, treatment and prognosis nursing.

Disclosed are methods and agents for treating heart failure. More particularly, the present disclosure relates to the use of CD14 antagonist antigen-binding molecules for treating heart failure, including alleviating, reducing or reversing adverse cardiac structural remodeling, improving cardiac contractile function, improving ejection fraction (e.g., left ventricular ejection fraction), left ventricular end-systolic volume, left ventricular end- diastolic volume, left ventricular akinesia, left ventricular dilatation, and / or left ventricular hypertrophy, reducing dyspnea, improving congestion score and / or patient perception of their health status and / or reducing neutrophil / lymphocyte ratio.

This invention discloses a traditional Chinese medicine composition for treating heart failure and insufficient cardiac function, belonging to the field of pet medicine technology. The composition, based on a 30 kg pet, is made from the following raw materials in parts by weight: ginseng 5-7g, astragalus 18-22g, salvia miltiorrhiza 8-12g, lepidium seed 4-6g, aconite root 1-3g, alisma 8-12g, poria cocos 8-12g, polygonatum odoratum 4-6g, cinnamon twig 2-4g, chuanxiong rhizome 1-3g, coptis chinensis root 1-3g, and licorice root 2-4g. This composition follows the principles of invigorating qi and warming yang, promoting blood circulation and removing blood stasis, and promoting diuresis and reducing swelling. It can effectively improve heart failure, insufficient cardiac function, and insufficient cardiac output in pets, increase left ventricular ejection fraction and cardiac output, and reduce myocardial damage indicators. It has definite clinical efficacy, high safety, and few toxic side effects, is suitable for the physiological characteristics of dogs, cats, and other pets, and has a simple preparation process, making it suitable for widespread clinical application in pets.

The application discloses a surgical risk prediction method and device and a storage medium, and relates to the technical field of medical treatment. The method comprises the following steps: acquiring preoperative multidimensional evaluation information of a target object; wherein the multidimensional evaluation information comprises a left ventricular ejection fraction, a first surgical risk score, a second surgical risk score, an NT-proBNP value, a systolic pulmonary artery pressure and an extracorporeal life support application state; inputting the preoperative multidimensional evaluation information into a surgical risk assessment model to obtain a surgical risk prediction result of the target object; wherein the surgical risk prediction result comprises at least one of a surgical risk grade, a total mortality risk value, a composite adverse event risk value and a predicted left ventricular ejection fraction change amount.

The invention discloses a real-time left ventricle ejection fraction monitoring method and device based on artificial intelligence image analysis, and relates to the field of image processing.The method comprises the steps that an X-ray perspective / angiography image sequence of a patient in the whole process of an operation is obtained, image segmentation is carried out, and a left ventricle profile diagram corresponding to each X-ray perspective / angiography image is obtained; constructing a training sample set according to each left ventricular profile diagram and the corresponding left ventricular ejection fraction; and training a machine learning model by using the left ventricular profile diagram in the training sample set and the corresponding left ventricular ejection fraction to obtain a left ventricular ejection fraction prediction model. According to the method, the left ventricular contour is extracted based on the X-ray perspective / angiography image, then the machine learning model is applied to predict the left ventricular ejection fraction, and the left ventricular ejection fraction of a patient can be monitored in real time in a cardiovascular disease operation.

The application provides application of a monascus composition in preparation of a medicine for preventing and / or treating coronary microcirculation disorder, wherein the monascus composition comprises one or more of mulberry bark, mulberry branch and mulberry leaf, monascus and pueraria. When the monascus composition is applied in preparation of the medicine for preventing and / or treating coronary microcirculation disorder, the following effects can be achieved: 1) improving microvascular structure abnormality (increasing myocardial microvascular density MVD, reducing perivascular edema of microvessels, improving lumen stenosis phenomenon, and good endothelial cell condition); 2) improving microvascular obstruction (pathological results show that the content of microvessels is reduced); 3) improving abnormal microvascular vasomotor function (increasing NO); 4) improving blood lipid metabolism disorder; and 5) improving heart function (increasing left ventricular ejection fraction LVEF and left ventricular short axis shortening rate LVFS, increasing left ventricular internal pressure maximum rising rate LV+dp / dtmax and left ventricular internal pressure maximum falling rate LV‑dp / dtmax).